Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).

NCT05191680 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT05191680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05191680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Phase 2
Overall status
Recruiting
Start date
April 24, 2023
Completion date
October 31, 2029
Enrollment
90 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer